A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

  • STATUS
    Recruiting
  • End date
    Aug 17, 2022
  • participants needed
    445
  • sponsor
    MacroGenics
Updated on 17 February 2021
cancer
measurable disease
HER2
solid tumour
erbb2

Summary

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD013 and establish the maximum tolerated dose (MTD) of MGD013. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of MGD013 will also be assessed.

Description

This is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary antitumor activity of MGD013 administered by IV infusion every 2 weeks. The study consists of a Dose Escalation Phase to determine the MTD or maximum administered dose (MAD) of MGD013 if no MTD is defined, followed by a Cohort Expansion Phase to further define the safety and initial antitumor activity of MGD013 with the dose established in the Dose Escalation Phase.

In the Dose Escalation Phase, MGD013 will be evaluated in sequential escalating flat doses in successive cohorts of 1 to 6 patients each. Upon completion of the Dose Escalation Phase, a Cohort Expansion Phase will be initiated at the MTD/MAD.

Patients with unresectable, locally advanced or metastatic solid tumors of any histology will be enrolled in the Dose Escalation Phase. The Cohort Expansion Phase will be limited to selected cohorts of patients with unresectable, locally advanced or metastatic solid tumors or hematologic malignancies for whom there is no available therapy likely to confer clinical benefit. Two additional cohorts will enroll patients with gastric/gastroesophageal cancer or epithelial ovarian cancer, with MGD013 given every 3 weeks.

A separate cohort will evaluate the combination of MGD013 with margetuximab (anti-HER2 monoclonal antibody) in approximately 99 patients, in subgroups with HER2-positive gastric or gastroesophageal cancer, HER2-positive breast cancer, and any other HER2-positive cancer.

Details
Condition Ovarian disorder, Hematologic Malignancy, Diffuse Large B-Cell Lymphoma, Blood disorder, Ovarian Cancer, Gastropathy, Gastric Cancer, Stomach Discomfort, Ovarian Function, Advanced Solid Tumors, HER2 Positive Breast Cancer, Gastroesophageal Cancer, Gastric Carcinoma, Recurrent Ovarian Cancer, HER2 Positive Gastric Cancer, Blood Cancer, Stomach Cancer, Hematologic Cancer, Hematological Disorders, Hematologic Neoplasms, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, gastric cancers, her2/neu-positive breast cancer, her2-positive breast cancer, diffuse large cell lymphoma, diffuse large b cell lymphoma, ovarian tumors, hematological malignancy, hematologic malignancies, hematological tumor, haematological malignancy, hematological malignancies
Treatment MGD013, MGD013 in combination with margetuximab
Clinical Study IdentifierNCT03219268
SponsorMacroGenics
Last Modified on17 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically proven, locally advanced unresectable or metastatic solid tumors (or hematologic malignancies, Cohort Expansion only) for whom no approved therapy with demonstrated clinical benefit is available or standard treatment was declined
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy 12 weeks
Measurable disease
Tissue specimen available for retrospective analysis of PD-1, PD-L1, LAG-3, and MHC-II expression
Acceptable laboratory parameters
HER2+ Cohort
Locally advanced or metastatic HER2+ locally advanced or metastatic solid tumors, regardless of organ of origin. i. The cancer must have progressed following standard therapy, or has progressed during or after HER2-directed therapy if approved and available for patients with HER2+ breast, gastric, or gastroesophageal junction cancer
ii. History of HER2 positivity defined as 3+ by IHC or 2+ by IHC in
combination with in situ hybridization (ISH) positivity most recent tumor
biopsy
All patients in the HER2+ cohort must be willing to provide consent for a baseline and on-treatment tumor biopsy during the screening period and within 14 days prior to Cycle 3 Day 1. Exceptions may be made based on a medical contraindication at the discretion of the Sponsor's Medical Monitor. This requirement will be discontinued after an adequate number of samples are collected, as determined by the Sponsor

Exclusion Criteria

Symptomatic central nervous system (CNS) metastases or primary CNS lymphoma
History of allogeneic bone marrow, stem-cell, or solid organ transplant
History of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing
Treatment with any systemic chemotherapy within 3 weeks prior to the initiation of study drug; treatment with biologics or investigational therapy within the 4 weeks prior to the initiation of study drug
Major surgery within 4 weeks prior to the initiation of study drug
Prior treatment with combination of monoclonal antibodies against PD-1 and LAG-3 (Cohort Expansion only)
Treatment with radiation therapy within 2 weeks prior to the initiation of study drug
Clinically significant cardiovascular disease
QTcF prolongation > 480 milliseconds
HER2+ cohort: left ventricular ejection fraction less than 50%
Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation
Active pneumonitis or history of non-infectious pneumonitis
Clinically significant gastrointestinal disorders
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug
Known history of positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome
Known history of hepatitis B (except in hepatocellular carcinoma) or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR)
Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
Dementia or altered mental status that would preclude understanding and rendering of informed consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note